Persister state-directed transitioning and vulnerability in melanoma
Heike Chauvistré(Vrije Universiteit Brussel), Alexander Roesch(University of Regensburg), Antonio Sechi(RWTH Aachen University), Ivan Bogeski(University of Göttingen), Renáta Váraljai(Vrije Universiteit Brussel), Susanne Horn(Vrije Universiteit Brussel), Samantha J. Stehbens(The University of Queensland), Felix C. E. Vogel(German Cancer Research Center), Batool Shannan(Vrije Universiteit Brussel), Markus Kaiser(University of Duisburg-Essen), Meenhard Herlyn(The Wistar Institute), Dirk Schadendorf(University of Mannheim), Iris Helfrich(West German Heart and Vascular Center Essen), Clemens Krepler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kirujan Jeyakumar(TU Dortmund University), Oliver Keminer(Fraunhofer Institute for Translational Medicine and Pharmacology), Annette Paschen(University of Duisburg-Essen), Marc Remke(Düsseldorf University Hospital), Sheraz Gul(Fraunhofer Institute for Translational Medicine and Pharmacology), Nikolas K. Haass(The University of Queensland), Sheena M. Daignault-Mill(The University of Queensland), Stefanie Egetemaier, Linda Kubat(Essen University Hospital), Jürgen C. Becker(German Cancer Research Center), Jan Förster(Essen University Hospital), Daniel Rauh(TU Dortmund University), Christine S. Gibhardt(University of Göttingen), Farnusch Kaschani(University of Duisburg-Essen), Michael Ehrmann(University of Duisburg-Essen), Daniel Picard(Heidelberg University), José Neptuno Rodríguez‐López(Universidad de Murcia), Vito W. Rebecca(The Wistar Institute), Qin Liu(Shengli Oilfield Central Hospital), Robert J. Ju(The University of Queensland), Xiangfan Yin(The Wistar Institute), Smiths Lueong(German Cancer Research Center)
Cited by 35
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
|Cell|2018|1.4k
Colorectal carcinoma antigens detected by hybridoma antibodies
|Somatic Cell and Molecular Genetics|1979|1.4k
A Tumorigenic Subpopulation with Stem Cell Properties in Melanomas
|Cancer Research|2005|1.3k